|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
KR100987051B1
(ko)
*
|
2008-12-23 |
2010-10-11 |
한국수력원자력 주식회사 |
입자추적법을 이용한 복잡흐름장에서의 오염 물질 이동 수치모사 방법
|
|
RS56770B1
(sr)
|
2011-03-11 |
2018-04-30 |
Celgene Corp |
Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
|
|
JP2015508414A
(ja)
|
2012-01-12 |
2015-03-19 |
イエール ユニバーシティ |
Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
|
|
CN104755472A
(zh)
|
2012-09-04 |
2015-07-01 |
细胞基因公司 |
3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US9962452B2
(en)
|
2013-02-04 |
2018-05-08 |
Zhuhai Beihai Biotech Co., Ltd. |
Soluble complexes of drug analogs and albumin
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
PE20160685A1
(es)
|
2013-10-04 |
2016-07-23 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
CN119591582A
(zh)
*
|
2014-04-14 |
2025-03-11 |
阿尔维纳斯运营股份有限公司 |
基于酰亚胺的蛋白水解调节剂和相关使用方法
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EP3139942B1
(en)
|
2014-05-05 |
2019-12-18 |
Bioventures, Llc |
COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
|
|
US9937259B2
(en)
|
2014-06-27 |
2018-04-10 |
Zhuhai Beihai Biotech Co., Ltd. |
Abiraterone derivatives and non-covalent complexes with albumin
|
|
EP3177144A4
(en)
|
2014-07-22 |
2018-01-24 |
Bioventures, LLC. |
Compositions and methods for selectively depleting senescent cells
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
WO2016065139A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Fl Therapeutics Llc |
3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
HK1245791A1
(zh)
*
|
2015-01-20 |
2018-08-31 |
阿尔维纳斯运营股份有限公司 |
用於雄激素受体的靶向降解的化合物和方法
|
|
JP7269731B2
(ja)
|
2015-03-18 |
2023-05-09 |
アルビナス・オペレーションズ・インコーポレイテッド |
標的タンパク質の分解向上のための化合物および方法
|
|
GB201506871D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
KR20240119196A
(ko)
*
|
2015-06-04 |
2024-08-06 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드계 조절인자 및 관련된 이용 방법
|
|
WO2016197114A1
(en)
*
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
CN108137507A
(zh)
|
2015-07-10 |
2018-06-08 |
阿尔维纳斯股份有限公司 |
基于mdm2的蛋白水解调节剂和相关的使用方法
|
|
AU2016301196B2
(en)
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
|
EP3337476A4
(en)
*
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP3341007B1
(en)
|
2015-08-28 |
2020-12-23 |
Cornell University |
Malt1 inhibitors and uses thereof
|
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
WO2017117474A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
WO2017117473A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
JP6967522B2
(ja)
|
2016-02-15 |
2021-11-17 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体
|
|
CA3017740A1
(en)
|
2016-03-16 |
2017-09-21 |
Pearlie BURNETTE |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
AU2017246453A1
(en)
|
2016-04-06 |
2018-11-08 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
JP7037500B2
(ja)
*
|
2016-04-06 |
2022-03-16 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｍｄｍ２タンパク質分解剤
|
|
AU2017250076B2
(en)
*
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
|
CN109152933B
(zh)
*
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
WO2017185031A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
AU2017254702B2
(en)
*
|
2016-04-22 |
2020-12-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
|
|
JP6921114B2
(ja)
*
|
2016-04-22 |
2021-08-18 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
サイクリン依存性キナーゼ８（ｃｄｋ８）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ８の分解および使用法
|
|
EP3892272B1
(en)
|
2016-04-22 |
2024-07-24 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
EP3455219A4
(en)
*
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109641874A
(zh)
*
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
US11883381B2
(en)
|
2016-05-12 |
2024-01-30 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
|
CA3025806C
(en)
|
2016-06-23 |
2023-04-04 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
|
|
CA3025805A1
(en)
*
|
2016-06-23 |
2017-12-28 |
James Bradner |
Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
|
|
GB201614134D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
ES2857743T3
(es)
*
|
2016-09-13 |
2021-09-29 |
Univ Michigan Regents |
1,4-diazepinas fusionadas como degradadores de proteína BET
|
|
CN110062759B
(zh)
*
|
2016-09-13 |
2022-05-24 |
密执安大学评议会 |
作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
|
|
GB2554071A
(en)
*
|
2016-09-14 |
2018-03-28 |
Univ Dundee |
Small molecules
|
|
ES2975558T3
(es)
|
2016-09-15 |
2024-07-09 |
Arvinas Inc |
Derivados de indol como degradantes de receptor de estrógeno
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
LT3660004T
(lt)
*
|
2016-10-11 |
2023-06-12 |
Arvinas Operations, Inc. |
Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
|
|
WO2018075820A2
(en)
*
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018074563A1
(ja)
*
|
2016-10-21 |
2018-04-26 |
学校法人 慶應義塾 |
フェニルフタルイミド修飾体及びそれを有効成分とする医薬組成物
|
|
AU2017348322B8
(en)
*
|
2016-10-28 |
2021-12-23 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating EZH2-mediated cancer
|
|
WO2018085247A1
(en)
|
2016-11-01 |
2018-05-11 |
Cornell University |
Compounds for malt1 degradation
|
|
EP3535265A4
(en)
*
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
AU2017363252B2
(en)
*
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
WO2018098280A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
WO2018102725A1
(en)
|
2016-12-01 |
2018-06-07 |
Arvinas, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
AU2017370694A1
(en)
|
2016-12-08 |
2019-07-25 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating CDK4/6-mediated cancer
|
|
RU2019121527A
(ru)
*
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
EP3559006A4
(en)
*
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
EP3558994A4
(en)
*
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
|
|
US11191741B2
(en)
*
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CN107056772A
(zh)
*
|
2017-01-23 |
2017-08-18 |
中国药科大学 |
基于cereblon配体诱导BET降解的双功能分子及其制备和应用
|
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
|
EP3577109A4
(en)
*
|
2017-01-31 |
2020-11-18 |
Arvinas Operations, Inc. |
CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
KR102125661B1
(ko)
*
|
2017-02-13 |
2020-06-22 |
강푸 바이오파마슈티칼즈 리미티드 |
전립선암 치료용 조합, 약학 조성물 및 치료 방법
|
|
US11261179B2
(en)
|
2017-04-14 |
2022-03-01 |
University Of Dundee |
Small molecules
|
|
CN107033147B
(zh)
*
|
2017-04-25 |
2018-08-21 |
东南大学 |
一种bet/hdac双靶点抑制剂及其制备方法和应用
|
|
AU2018258581A1
(en)
|
2017-04-28 |
2019-11-07 |
Quartz Therapeutics, Inc. |
RAF-degrading conjugate compounds
|
|
CN108947888B
(zh)
*
|
2017-05-23 |
2021-05-07 |
南京理工大学 |
一种在水相中钯催化合成3-取代异吲哚啉酮的方法
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
WO2019006426A2
(en)
|
2017-06-30 |
2019-01-03 |
Massachusetts Institute Of Technology |
RAMIFIED MULTIFUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF
|
|
GB201710620D0
(en)
*
|
2017-07-03 |
2017-08-16 |
Glaxosmithkline Intellectual Property Ltd |
Targeted protein degradation
|
|
EP4310496A3
(en)
|
2017-07-12 |
2024-12-04 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
WO2019023553A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Arvinas, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
CN109422733A
(zh)
*
|
2017-09-03 |
2019-03-05 |
上海美志医药科技有限公司 |
一类抑制并降解酪氨酸蛋白激酶alk的化合物
|
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
KR20200086278A
(ko)
*
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
EP3676268A1
(en)
*
|
2017-10-20 |
2020-07-08 |
Dana-Farber Cancer Institute, Inc. |
Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
WO2019094772A1
(en)
*
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l degraders and methods of treatment therewith
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019109415A1
(zh)
*
|
2017-12-04 |
2019-06-13 |
清华大学 |
一种靶向降解hmgcr的化合物及其应用
|
|
AU2018386184B2
(en)
|
2017-12-13 |
2023-03-09 |
Dana-Farber Cancer Institute, Inc. |
Compounds for the degradation of STK4 and treatment of hematologic malignancies
|
|
EP3725771B1
(en)
*
|
2017-12-13 |
2026-02-04 |
Shanghaitech University |
Alk protein degradation agent and anti-tumor application thereof
|
|
JP2021506848A
(ja)
|
2017-12-18 |
2021-02-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US20210015942A1
(en)
*
|
2018-01-10 |
2021-01-21 |
Development Center For Biotechnology |
Antibody protac conjugates
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
EP3743069B1
(en)
|
2018-01-22 |
2025-08-06 |
BioVentures, LLC |
Bcl-2 proteins degraders for cancer treatment
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
CA3090414A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Lei Wu |
Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof
|
|
WO2019173516A1
(en)
|
2018-03-06 |
2019-09-12 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (akt) degradation / disruption compounds and methods of use
|
|
WO2019170150A1
(zh)
|
2018-03-09 |
2019-09-12 |
上海科技大学 |
蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
KR20210018199A
(ko)
*
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
CN110317192A
(zh)
*
|
2018-03-28 |
2019-10-11 |
上海美志医药科技有限公司 |
一类具有降解雄激素受体活性的化合物
|
|
KR20240130153A
(ko)
*
|
2018-04-01 |
2024-08-28 |
아비나스 오퍼레이션스, 인코포레이티드 |
Brm을 표적으로 하는 화합물 및 관련 사용 방법
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
US12226424B2
(en)
|
2018-04-09 |
2025-02-18 |
Shanghaitech University |
Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
|
|
EP3774772A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019200367A1
(en)
|
2018-04-13 |
2019-10-17 |
Massachusetts Institute Of Technology |
Brush prodrugs and uses thereof
|
|
WO2019204354A1
(en)
*
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
EP3556760A1
(en)
|
2018-04-19 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN111741769B
(zh)
*
|
2018-04-20 |
2022-09-16 |
四川科伦博泰生物医药股份有限公司 |
一种多功能化合物、其制备方法及其在医药上的应用
|
|
US12084423B2
(en)
|
2018-05-18 |
2024-09-10 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN112533918A
(zh)
|
2018-06-13 |
2021-03-19 |
安菲斯塔治疗有限责任公司 |
用于靶向Rpn11的双功能分子
|
|
CA3104298A1
(en)
|
2018-06-21 |
2019-12-26 |
Icahn School Of Medicine At Mount Sinai |
Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
|
|
WO2020006264A1
(en)
*
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (crbn)
|
|
WO2020007322A1
(zh)
*
|
2018-07-04 |
2020-01-09 |
清华大学 |
一种靶向降解bet蛋白的化合物及其应用
|
|
CN108794453A
(zh)
*
|
2018-07-05 |
2018-11-13 |
清华大学 |
一种靶向降解fak蛋白的化合物及其应用
|
|
JP2021529807A
(ja)
*
|
2018-07-05 |
2021-11-04 |
アイカーン スクール オブ メディスン アット マウント シナイ |
タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
CU20210002A7
(es)
|
2018-07-10 |
2021-08-06 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EA202190248A1
(ru)
*
|
2018-07-11 |
2021-06-16 |
Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. |
Димерные иммуномодулирующие соединения против механизмов на основе цереблона
|
|
US12011432B2
(en)
|
2018-07-18 |
2024-06-18 |
Case Western Reserve University |
Method of modulating ribonucleotide reductase
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
CN112533898A
(zh)
|
2018-07-31 |
2021-03-19 |
日商泛美克斯股份有限公司 |
杂环化合物
|
|
US11707452B2
(en)
*
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
AU2019323446B2
(en)
|
2018-08-22 |
2025-01-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
EP3846800A4
(en)
|
2018-09-04 |
2022-08-24 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
IL319737A
(en)
*
|
2018-09-07 |
2025-05-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides
|
|
CN111018857B
(zh)
*
|
2018-10-09 |
2023-06-02 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
TW202037381A
(zh)
|
2018-10-24 |
2020-10-16 |
瑞士商赫孚孟拉羅股份公司 |
綴合化學降解誘導劑及使用方法
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
BR112021012186A2
(pt)
|
2018-12-19 |
2021-08-31 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
CN119219606A
(zh)
|
2018-12-19 |
2024-12-31 |
细胞基因公司 |
经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
US20220081435A1
(en)
*
|
2019-01-03 |
2022-03-17 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2020160295A1
(en)
*
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3919127A4
(en)
*
|
2019-02-02 |
2022-12-07 |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
BRD4 TARGETED UBIQUINATION DEGRADATION COMPOUND, METHOD OF PREPARATION AND APPLICATION THEREOF
|
|
WO2020163170A1
(en)
*
|
2019-02-05 |
2020-08-13 |
The Board Of Regents Of The University Of Texas System |
Trapping-free parp inhibitors
|
|
KR102876423B1
(ko)
*
|
2019-02-07 |
2025-10-24 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
WO2020176424A1
(en)
*
|
2019-02-25 |
2020-09-03 |
Chdi Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
|
US12582641B2
(en)
|
2019-02-25 |
2026-03-24 |
Shanghaitech University |
Sulfur-containing compound based on glutarimide skeleton and application thereof
|
|
CA3131804A1
(en)
|
2019-03-01 |
2020-09-10 |
Ontario Institute For Cancer Research (Oicr) |
Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
AU2020270908B2
(en)
*
|
2019-04-09 |
2025-09-25 |
Beth Israel Deaconess Medical Center, Inc. |
Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use
|
|
MA55628A
(fr)
|
2019-04-12 |
2022-02-16 |
C4 Therapeutics Inc |
Agents de dégradation tricycliques d'ikaros et d'aiolos
|
|
US12414995B2
(en)
|
2019-04-16 |
2025-09-16 |
Northwestern University |
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
|
|
KR20220004100A
(ko)
*
|
2019-04-18 |
2022-01-11 |
하이노바 파마슈티컬스 인코포레이티드 |
안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
|
|
US12465648B2
(en)
|
2019-05-06 |
2025-11-11 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of HPK1
|
|
ES2989387T3
(es)
|
2019-05-31 |
2024-11-26 |
Janssen Pharmaceutica Nv |
Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020249048A1
(zh)
*
|
2019-06-12 |
2020-12-17 |
上海科技大学 |
Alk蛋白调节剂及其抗肿瘤应用
|
|
CN112094266B
(zh)
*
|
2019-06-17 |
2023-03-21 |
中国科学院上海药物研究所 |
一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
|
|
CN110372669B
(zh)
*
|
2019-06-19 |
2020-11-24 |
浙江省医学科学院 |
一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
|
|
US12624015B2
(en)
|
2019-06-24 |
2026-05-12 |
University Of Iowa Research Foundation |
JNK inhibitors as anticancer agents
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021011913A1
(en)
|
2019-07-17 |
2021-01-21 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
CN112321566B
(zh)
|
2019-08-05 |
2022-06-10 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
WO2021026349A1
(en)
|
2019-08-08 |
2021-02-11 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Combination therapy for treatment of cancer
|
|
ES3061133T3
(en)
|
2019-08-26 |
2026-03-31 |
Arvinas Operations Inc |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
WO2021047627A1
(zh)
*
|
2019-09-12 |
2021-03-18 |
南京明德新药研发有限公司 |
一种可降解蛋白的并环类化合物及其应用
|
|
CN110563703B
(zh)
*
|
2019-09-18 |
2021-04-09 |
浙江省医学科学院 |
基于crbn配体诱导parp-1降解的化合物及制备方法和应用
|
|
US11420956B2
(en)
|
2019-09-23 |
2022-08-23 |
Accutar Biotechnology Inc. |
Ureas having Androgen Receptor degradation activity and uses thereof
|
|
US10836749B1
(en)
*
|
2019-09-23 |
2020-11-17 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
WO2021067606A1
(en)
|
2019-10-01 |
2021-04-08 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
AU2020368453A1
(en)
|
2019-10-16 |
2022-04-21 |
Massachusetts Institute Of Technology |
Brush prodrugs and uses thereof
|
|
US12310975B2
(en)
*
|
2019-10-17 |
2025-05-27 |
Arvinas Operations, Inc. |
Modulators of BCL6 proteolysis and associated methods of use
|
|
CN115135313A
(zh)
*
|
2019-10-22 |
2022-09-30 |
阿维纳斯企业公司 |
治疗前列腺癌的方法
|
|
CN112707900B
(zh)
*
|
2019-10-24 |
2022-06-10 |
上海科技大学 |
蛋白降解剂及其在疾病治疗中的应用
|
|
CN110713480B
(zh)
*
|
2019-10-28 |
2021-02-26 |
浙江省医学科学院 |
AChE蛋白降解物及其制备方法和应用
|
|
CN110746400B
(zh)
*
|
2019-11-07 |
2021-12-17 |
郑州大学 |
一种靶向雄激素受体的荧光探针及其制备方法
|
|
CN110790750B
(zh)
*
|
2019-11-07 |
2021-09-21 |
郑州大学 |
一种邻苯二甲酰亚胺类选择性雄激素受体降解剂及其制备方法和用途
|
|
EP4072591A4
(en)
|
2019-12-10 |
2024-06-05 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADER AND USES THEREOF
|
|
WO2021121261A1
(zh)
*
|
2019-12-16 |
2021-06-24 |
北京泰德制药股份有限公司 |
抑制并诱导降解egfr激酶的化合物
|
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
WO2021126974A1
(en)
*
|
2019-12-17 |
2021-06-24 |
Orionis Biosciences, Inc. |
Bifunctional agents for protein recruitment and/or degradation
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4077309A1
(en)
|
2019-12-19 |
2022-10-26 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
|
EP4083020A4
(en)
|
2019-12-23 |
2024-01-24 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
PREPARATION METHOD AND APPLICATION OF PROTEIN DEGRADATION AGENT COMPOUND
|
|
US20230117831A1
(en)
*
|
2020-01-08 |
2023-04-20 |
The Broad Institute, Inc. |
Multi-functional chimeric molecules
|
|
WO2021141662A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Massachusetts Institute Of Technology |
Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
|
|
AU2021213822A1
(en)
|
2020-01-31 |
2022-09-22 |
Avilar Therapeutics, Inc. |
ASGPR-binding compounds for the degradation of extracellular proteins
|
|
CN113248484A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海强睿生物科技有限公司 |
一种特异性降解tau蛋白的小分子化合物及其应用
|
|
KR20210103973A
(ko)
*
|
2020-02-14 |
2021-08-24 |
보로노이 주식회사 |
단백질 키나아제 분해 유도 화합물 및 이의 용도
|
|
US12528814B2
(en)
|
2020-02-19 |
2026-01-20 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
JP7692924B2
(ja)
*
|
2020-02-26 |
2025-06-16 |
クルゲン（シャンハイ），インク． |
トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
|
|
IL295709A
(en)
|
2020-03-05 |
2022-10-01 |
C4 Therapeutics Inc |
Compounds for targeted degradation of brd9
|
|
CN113387930B
(zh)
*
|
2020-03-11 |
2022-07-12 |
苏州开拓药业股份有限公司 |
一种双官能化合物及其制备方法和用途
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
IL296451B2
(en)
|
2020-03-19 |
2026-05-01 |
Kymera Therapeutics Inc |
MDM2 joints and their uses
|
|
KR102624481B1
(ko)
*
|
2020-03-20 |
2024-01-16 |
(주)프레이저테라퓨틱스 |
p38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물
|
|
US11858940B2
(en)
|
2020-03-21 |
2024-01-02 |
Arvinas Operations, Inc. |
Selective modulators of mutant LRRK2 proteolysis and associated methods of use
|
|
US12053469B2
(en)
|
2020-03-21 |
2024-08-06 |
Arvinas Operations, Inc. |
Indazole based compounds and associated methods of use
|
|
KR20210122164A
(ko)
|
2020-03-27 |
2021-10-08 |
(주) 업테라 |
Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
|
|
EP4132655A1
(en)
|
2020-04-06 |
2023-02-15 |
Arvinas Operations, Inc. |
Compounds and methods for targeted degradation of kras
|
|
US11358992B2
(en)
*
|
2020-04-17 |
2022-06-14 |
Uppthera |
Cell-penetrating cereblon recombinant fusion protein and use thereof
|
|
CN115835886A
(zh)
*
|
2020-04-23 |
2023-03-21 |
衣阿华大学研究基金会 |
Gper蛋白水解靶向嵌合体
|
|
ES3014370T3
(en)
*
|
2020-04-28 |
2025-04-22 |
Rhizen Pharmaceuticals Ag |
Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
|
|
WO2021219077A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
EP4146642A1
(en)
|
2020-05-09 |
2023-03-15 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
|
GB202007106D0
(en)
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4166550A4
(en)
|
2020-06-12 |
2024-08-07 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
PHTHALAZINONE COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
|
|
CA3173629A1
(en)
|
2020-06-19 |
2021-12-13 |
Cosimo Dolente |
Braf degraders
|
|
US12415799B2
(en)
*
|
2020-06-28 |
2025-09-16 |
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
Indazole-fused cyclic compound
|
|
WO2022017442A1
(zh)
*
|
2020-07-24 |
2022-01-27 |
恩瑞生物医药科技（上海）有限公司 |
双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
CN114057770B
(zh)
*
|
2020-08-06 |
2023-05-02 |
成都先导药物开发股份有限公司 |
靶向egfr蛋白降解的双功能化合物
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
AU2021361044A1
(en)
*
|
2020-10-14 |
2023-06-08 |
C4 Therapeutics, Inc. |
Tricyclic heterobifunctional compounds for degradation of targeted proteins
|
|
MX2023004545A
(es)
|
2020-10-21 |
2023-07-05 |
Arvinas Operations Inc |
Compuestos y métodos para la degradación dirigida de la proteína del receptor de andrógenos.
|
|
US20220144809A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN112341436A
(zh)
*
|
2020-11-20 |
2021-02-09 |
中国药科大学 |
基于靶向抑制和降解alk的苯并咔唑类蛋白水解靶向嵌合分子、制备方法及用途
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
|
|
CN112480081B
(zh)
*
|
2020-12-07 |
2022-02-22 |
沈阳药科大学 |
一种基于Cereblon配体诱导SHP2蛋白降解的双功能分子化合物
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
AU2021402911A1
(en)
*
|
2020-12-14 |
2023-07-06 |
Biotheryx, Inc. |
Pde4 degraders, pharmaceutical compositions, and therapeutic applications
|
|
WO2022147465A1
(en)
|
2020-12-30 |
2022-07-07 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4023649A1
(en)
*
|
2020-12-30 |
2022-07-06 |
Industrial Technology Research Institute |
Androgen receptor binding bifunctional molecules
|
|
WO2022146151A1
(en)
*
|
2020-12-30 |
2022-07-07 |
Captor Therapeutics S.A. |
Novel compounds which bind to cereblon, and methods of use thereof
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
US12569564B2
(en)
|
2021-01-23 |
2026-03-10 |
Newave Pharmaceutical Inc. |
Spirocyclic MDM2 modulator and uses thereof
|
|
KR20230170644A
(ko)
|
2021-02-02 |
2023-12-19 |
르 라보레또레 쎄르비에르 |
선택적 bcl-xl protac 화합물 및 사용 방법
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
CN116848120B
(zh)
|
2021-02-15 |
2026-02-13 |
安斯泰来制药株式会社 |
用于诱导g12d突变kras蛋白分解的喹唑啉化合物
|
|
CN117321046A
(zh)
*
|
2021-03-19 |
2023-12-29 |
阿维纳斯企业公司 |
基于吲唑的化合物和相关使用方法
|
|
JP2024512501A
(ja)
|
2021-03-19 |
2024-03-19 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
インダゾール系化合物及び関連使用方法
|
|
BR112023019967A2
(pt)
*
|
2021-03-29 |
2023-11-14 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
|
|
CA3214806A1
(en)
|
2021-04-16 |
2022-10-20 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
CA3217892A1
(en)
*
|
2021-05-03 |
2022-11-10 |
Joel Mcintosh |
Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
|
|
EP4334360A2
(en)
|
2021-05-03 |
2024-03-13 |
Avilar Therapeutics, Inc. |
Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
|
|
BR112023023065A2
(pt)
|
2021-05-05 |
2024-01-30 |
Biogen Ma Inc |
Compostos para direcionar a degradação da tirosina quinase de bruton
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
JP2024523839A
(ja)
|
2021-06-08 |
2024-07-02 |
シーフォー セラピューティクス， インコーポレイテッド |
突然変異体ｂｒａｆを分解する療法薬
|
|
WO2022266258A1
(en)
|
2021-06-15 |
2022-12-22 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of irak-4
|
|
CN113481289B
(zh)
*
|
2021-06-22 |
2022-03-29 |
天津见康华美医学诊断技术有限公司 |
一种铁粒幼红细胞性贫血检测引物组合物及应用
|
|
CN113354619B
(zh)
*
|
2021-06-24 |
2024-03-19 |
皖南医学院 |
一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
|
|
US20250312468A1
(en)
|
2021-07-02 |
2025-10-09 |
Merck Patent Gmbh |
Anti-protac antibodies and complexes
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
KR20240035526A
(ko)
|
2021-07-07 |
2024-03-15 |
바이오젠 엠에이 인코포레이티드 |
Irak4 단백질의 분해를 표적하는 화합물
|
|
JP2024525580A
(ja)
|
2021-07-07 |
2024-07-12 |
バイオジェン・エムエイ・インコーポレイテッド |
Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
|
|
CN113278023B
(zh)
*
|
2021-07-22 |
2021-10-15 |
上海睿跃生物科技有限公司 |
含氮杂环化合物及其制备方法和应用
|
|
US20240353397A1
(en)
*
|
2021-08-12 |
2024-10-24 |
Ramot At Tel-Aviv University Ltd. |
Markers of resistance and disease tolerance and uses thereof
|
|
EP4367118B1
(en)
|
2021-08-18 |
2025-01-29 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115772210A
(zh)
*
|
2021-09-08 |
2023-03-10 |
苏州开拓药业股份有限公司 |
硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途
|
|
WO2023038500A1
(ko)
*
|
2021-09-13 |
2023-03-16 |
주식회사 유빅스테라퓨틱스 |
Enl 단백질 분해용 화합물 및 이들의 의약 용도
|
|
US20240409528A1
(en)
*
|
2021-10-01 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
EP4423086A1
(en)
|
2021-10-25 |
2024-09-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
|
JPWO2023074780A1
(enExample)
*
|
2021-10-27 |
2023-05-04 |
|
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
CN118679160A
(zh)
|
2021-11-24 |
2024-09-20 |
阿维纳斯运营公司 |
Brm靶向化合物和相关的使用方法
|
|
US20250064945A1
(en)
|
2021-11-24 |
2025-02-27 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
CN118234726A
(zh)
|
2021-11-25 |
2024-06-21 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
EP4452933A1
(en)
|
2021-12-20 |
2024-10-30 |
Massachusetts Institute of Technology |
Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent
|
|
WO2023119677A1
(en)
|
2021-12-24 |
2023-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising a quinazoline compound
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
CN114410773B
(zh)
*
|
2022-01-27 |
2024-05-03 |
宁波大学 |
用于预测或诊断抑郁症复发的标志物组合及其应用
|
|
IL314437A
(en)
|
2022-01-31 |
2024-09-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
|
CN114560908B
(zh)
*
|
2022-03-11 |
2024-10-25 |
国家纳米科学中心 |
一种多肽protac分子及其制备方法和应用
|
|
KR20240162042A
(ko)
|
2022-03-11 |
2024-11-14 |
아스텔라스세이야쿠 가부시키가이샤 |
G12d 변이 kras 단백의 분해를 유도하기 위한 복소환 화합물
|
|
CN114907386B
(zh)
*
|
2022-03-11 |
2023-03-31 |
山东大学 |
一种hemtac小分子降解剂及其应用
|
|
CN116789636B
(zh)
*
|
2022-03-14 |
2026-01-30 |
北京康辰药业股份有限公司 |
双功能化合物及其制备方法、药物组合物和用途
|
|
CN119301111A
(zh)
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
US20240050577A1
(en)
*
|
2022-04-27 |
2024-02-15 |
Risen (Suzhou) Pharma Tech Co., Ltd. |
Cdk inhibitors and pharmaceutical uses thereof
|
|
CN119365198A
(zh)
|
2022-05-02 |
2025-01-24 |
艾斯巴赫生物有限公司 |
ALC1抑制剂的用途和与PARPi的协同作用
|
|
WO2023230059A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Newave Pharmaceutical Inc. |
Mdm2 degrader
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
AU2023298115A1
(en)
|
2022-06-27 |
2025-01-16 |
Relay Therapeutics, Inc. |
Estrogen receptor alpha degraders and use thereof
|
|
WO2024006776A1
(en)
|
2022-06-27 |
2024-01-04 |
Relay Therapeutics, Inc. |
Estrogen receptor alpha degraders and medical use thereof
|
|
KR20250028370A
(ko)
*
|
2022-06-30 |
2025-02-28 |
안혼 메디신즈 컴퍼니, 리미티드 |
이작용성 화합물 및 이작용성 화합물을 포함하는 약제학적 조성물, 및 이를 사용하여 안드로겐 수용체 관련 질환을 치료하기 위한 방법
|
|
WO2024020221A1
(en)
|
2022-07-21 |
2024-01-25 |
Arvinas Operations, Inc. |
Modulators of tyk2 proteolysis and associated methods of use
|
|
KR20250036820A
(ko)
|
2022-07-21 |
2025-03-14 |
아스텔라스세이야쿠 가부시키가이샤 |
G12d 변이 kras 단백에 작용하는 복소환 화합물
|
|
EP4565236A1
(en)
*
|
2022-08-02 |
2025-06-11 |
Beijing Neox Biotech Limited |
Bcl-xl degrading compounds
|
|
TW202412789A
(zh)
|
2022-08-05 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於誘導突變kras蛋白分解之雜環化合物
|
|
US20260042771A1
(en)
|
2022-08-09 |
2026-02-12 |
Astellas Pharma Inc. |
Heterocyclic compound for inducing degradation of g12v mutant kras protein
|
|
WO2024035780A1
(en)
*
|
2022-08-09 |
2024-02-15 |
Board Of Regents Of The University Of Nebraska |
Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
|
|
CA3264252A1
(en)
|
2022-08-12 |
2024-02-15 |
Astellas Pharma Inc. |
Combination of anticancer agents comprising a bifunctional compound with inhibitory activity against mutant Kirsten rat sarcoma virus G12D
|
|
TW202412809A
(zh)
|
2022-08-12 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
包含標靶療法的抗癌組合
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
CN120035586A
(zh)
*
|
2022-09-29 |
2025-05-23 |
江苏恒瑞医药股份有限公司 |
一种四氢萘类衍生物的可药用盐、晶型及制备方法
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
EP4600246A4
(en)
|
2022-10-03 |
2026-01-07 |
Public Univ Corp Yokohama City Univ |
BICYCLIC IMIDAZOPYRIDINE DERIVATIVES
|
|
EP4428134A1
(en)
|
2023-03-10 |
2024-09-11 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
AU2023416471A1
(en)
|
2022-12-27 |
2025-08-07 |
Merck Patent Gmbh |
Vhh anti-protac antibodies and complexes
|
|
TW202430187A
(zh)
|
2023-01-09 |
2024-08-01 |
美商亞文納營運公司 |
Ｂｃｌ６蛋白水解之調節劑及相關使用方法
|
|
WO2024150815A1
(ja)
|
2023-01-12 |
2024-07-18 |
田辺三菱製薬株式会社 |
セレブロンｅ３リガーゼ結合化合物、それを含む医薬組成物及びその製造方法
|
|
AU2024211840A1
(en)
|
2023-01-24 |
2025-07-03 |
Daiichi Sankyo Company, Limited |
Substituted benzene compound
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2024178348A2
(en)
|
2023-02-24 |
2024-08-29 |
Ppm Biopharma Llc |
Pleiotropic pathway modifier compounds and method of treating diseases
|
|
CN116854667A
(zh)
*
|
2023-05-17 |
2023-10-10 |
浙江工业大学 |
一种靶向降解pd-l1的蛋白水解靶向嵌合体及其应用
|
|
EP4714949A1
(en)
*
|
2023-05-18 |
2026-03-25 |
Ajou University Industry-Academic Cooperation Foundation |
Novel compounds capable of inducing osteogenic differentiation
|
|
WO2024240078A1
(en)
*
|
2023-05-19 |
2024-11-28 |
The Chinese University Of Hong Kong |
Compositions and methods related to protein labeling
|
|
WO2024240858A1
(en)
|
2023-05-23 |
2024-11-28 |
Valerio Therapeutics |
Protac molecules directed against dna damage repair system and uses thereof
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AR133028A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un degradador de todas las kras
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
EP4735438A2
(en)
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
AU2024310341A1
(en)
|
2023-06-30 |
2026-02-12 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
CN117263865B
(zh)
*
|
2023-08-04 |
2026-03-27 |
南开大学 |
以6,6-二甲基双环[3.1.1]-2-甲胺为疏水基团的蛋白降解剂及其制备方法、药物组合物和应用
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
GB202314126D0
(en)
|
2023-09-15 |
2023-11-01 |
Univ Oxford Innovation Ltd |
Compound and method
|
|
AU2024352092A1
(en)
|
2023-09-28 |
2026-04-09 |
Arvinas Operations, Inc. |
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2025070690A1
(ja)
|
2023-09-29 |
2025-04-03 |
第一三共株式会社 |
３－フェニルプロピルアミン誘導体
|
|
TW202523291A
(zh)
|
2023-11-02 |
2025-06-16 |
美商金橘生物科技公司 |
降解劑及其用途
|
|
WO2025122895A1
(en)
|
2023-12-08 |
2025-06-12 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
WO2025137500A1
(en)
|
2023-12-21 |
2025-06-26 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibition and degradation
|
|
WO2025184594A1
(en)
|
2024-02-29 |
2025-09-04 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
US12558428B2
(en)
|
2024-03-08 |
2026-02-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
WO2025213104A1
(en)
|
2024-04-05 |
2025-10-09 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of bcl6
|
|
CN118161490B
(zh)
*
|
2024-05-10 |
2024-07-23 |
昆明医科大学 |
一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用
|
|
WO2025262297A1
(en)
|
2024-06-21 |
2025-12-26 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
EP4667466A1
(en)
|
2024-06-21 |
2025-12-24 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
EP4667467A1
(en)
|
2024-06-21 |
2025-12-24 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
CN118459478B
(zh)
*
|
2024-07-09 |
2024-10-29 |
深圳大学 |
一种brd4蛋白靶向降解剂及其制备方法与应用
|
|
CN120154610B
(zh)
*
|
2025-05-19 |
2025-09-02 |
深圳大学 |
抗血栓小分子化合物bptu作为黏菌素佐剂协同抗革兰氏阴性菌的应用
|